STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
A Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent cardiovascular complications.
<p>A Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent cardiovascular complications.</p>